Weekly News Round-up – 9/4/21


In the news this week, Genmab suggests potential investment plans for spin-off biotechs. In other news, alternative COVID-19 vaccines offered to under-30s, and Acadia fails to achieve FDA approval for psychosis drug.
GENMAB CEO HINTS AT FUTURE INVESTMENT PLANS – CEO of Genmab, Jan van de Winkel, has suggested he would consider branching out with smaller, specialist biotech companies. The application of Genmab’s drugs in many fields, including autoimmune diseases, has shown potential to spin out smaller arms of the company in different disease areas, according to Van de Winkel. He stated he had ambitions for the company “to build an innovation powerhouse on our own.”
ALTERNATIVE COVID-19 VACCINE FOR THE YOUNGER POPULATION – After recent reviews by the Medicines and Healthcare Products Regulatory Agency (MHRA), under-30s in the UK will be offered alternative COVID-19 vaccines to the AstraZeneca jab. The final decision comes from the MHRA, with CEO Dr June Raine emphasising that the risks of the AstraZeneca vaccine were more ‘finely balanced’ with the benefits for the younger population.
ACADIA PSYCHOSIS DRUG DENIED FDA APPROVAL – Disappointment for Acadia as FDA rejects its psychosis drug, Nuplazid, for approval. Despite approval for the drug for Parkinson’s psychosis in 2016, the FDA denied approving Nuplazid for dementia-related psychosis. The decision came from the Division of Psychiatry, FDA, who inferred one of the reasons was that the “study data has had insufficient numbers of patients in the study with certain less common dementia subtypes.”
R&D
Artios Pharma and Novartis Collaboration Brings Hope for Next Generation Radioligand Therapy
That’s all for now. See you next week!
Charlotte Di Salvo, Junior Medical Writer
Proventa International

The Opportunities and Challenges of CNS Drug Delivery: An Interview with Marcie Glicksman, Enclear Therapies
Developing therapeutics that treat diseases of the brain especially has been an uphill struggle in terms of optimising drug delivery systems. While some pharma companies attempt to overcome hurdles like the blood-brain barrier, others are looking beyond this strategy to...
2 years agoThe Opportunities and Challenges of CNS Drug Delivery: An Interview with Marcie Glicksman, Enclear Therapies
Developing therapeutics that treat diseases of the brain especially has been an uphill struggle in terms of optimising drug delivery systems. While some pharma companies attempt to overcome hurdles like the blood-brain barrier, others are looking beyond this strategy to...
2 years ago
RNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years agoRNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years ago
Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years agoRaising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years ago